| Dr Jonathan Ashton Olsen, DO | |
|
11724 S State St, Draper, UT 84020-7163 | |
| (801) 576-2000 | |
| Not Available |
| Full Name | Dr Jonathan Ashton Olsen |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 14 Years |
| Location | 11724 S State St, Draper, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518287846 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 5607852-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Division University Of Utah Medical Center | 9638073497 | 61 |
| Granger Medical Clinic Pc | 3476465691 | 115 |
| Granger Medical Specialists Llc | 4587074356 | 157 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
| Entity Name | Granger Medical Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184657041 PECOS PAC ID: 3476465691 Enrollment ID: O20031105000159 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
| Entity Name | Dermatology Division University Of Utah Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922096114 PECOS PAC ID: 9638073497 Enrollment ID: O20031122000107 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
| Entity Name | U-u Pediatric Dermatology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235339193 PECOS PAC ID: 8729049002 Enrollment ID: O20041020000616 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
| Entity Name | Granger Medical Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376159368 PECOS PAC ID: 4587074356 Enrollment ID: O20201105002207 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan Ashton Olsen, DO 7181 S Campus View Dr Ste 200, West Jordan, UT 84084-4312 Ph: (801) 965-3505 | Dr Jonathan Ashton Olsen, DO 11724 S State St, Draper, UT 84020-7163 Ph: (801) 576-2000 |
News Archive
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.
Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.
A new model that would allow interventional radiologists (radiologists who specialize in fine needle aspiration, fine needle biopsy and radiofrequency ablation) to better estimate patient radiation skin doses during CT guided interventional procedures has been developed according to a study performed at the Agios Savvas and Konstantopoulio Hospitals in Athens, Greece.
A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.
› Verified 7 days ago
Dr. Duane Jones Harris, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 12422 S 450 E, Ste C, Draper, UT 84020 Phone: 801-553-1900 Fax: 801-553-9995 |